Short Interest in PicoCELA Inc. (NASDAQ:PCLA) Decreases By 89.5%

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 12,084 shares, a decrease of 89.5% from the November 30th total of 114,853 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 130,843 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 130,843 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd bought a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned about 0.16% of PicoCELA as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PicoCELA in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

PicoCELA Stock Down 35.5%

Shares of PicoCELA stock traded down $0.13 on Thursday, hitting $0.23. The stock had a trading volume of 19,166,725 shares, compared to its average volume of 41,410,808. The stock has a 50 day moving average of $0.32 and a 200 day moving average of $0.65. PicoCELA has a twelve month low of $0.12 and a twelve month high of $9.80. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.74 and a current ratio of 2.19.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.